PG

Prithi Gajula

Active Director Director DIN 10147007
DIN 10147007 First appointment May 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2023
Shareholding value •••• Premium profile

About Prithi Gajula

Data last updated:

Prithi Gajula is a Director at Novell Pharma Private Limited (since 2023). The company operates in Pharma. Novell Pharma Private Limited reported revenue of ₹75.4 Lakh (FY 2024).

DIN 10147007
Primary Designation Director
Industry Pharma
First Appointment 03 May 2023
Oldest Company Age 11 yrs
Largest company Novell Pharma Private Limited · ₹75.4 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Novell Pharma Private Limited U24230TG2015PTC098025
Director03 May 20232015₹75.4 Lakh (FY 2024)Active

Board colleagues of Prithi Gajula

NameDINCompanyDesignation
Sunil Sheari07112409Novell Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Novell Pharma Private Limited
Premium access

Shareholding and investment profile for Prithi Gajula

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Prithi Gajula

Prithi Gajula currently holds 1 directorship: Novell Pharma Private Limited (Director, since 03 May 2023, revenue ₹75.4 Lakh (FY 2024)).

Prithi Gajula was first appointed on 03 May 2023 as Director at Novell Pharma Private Limited.

The current boards of Prithi Gajula's companies include Sunil Sheari (Novell Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available